Nuclear Medicine or Radiopharmaceuticals Market Introduction

Nuclear Medicine or Radiopharmaceuticals Market is estimated to value over USD 5.7 billion by 2027 end and register a CAGR of over 4.5% during the forecast period 2020 to 2027.

Market research has predicted that the rise of ailments such as Parkinson's, Alzheimer’s, Cancer and Cardiac failure are reasons which have contributed to the nuclear medicine/radiopharmaceuticals market growth in the forecast period. New strides within neurological applications and major shifts in new products by various companies are aiding the demand for the affordability of radiopharmaceuticals. Imaging processes in nuclear medicine are non-invasive and can be used for treating a number of diseases, such as cancers,  neurological disorders and cardiovascular diseases.

Moreover, surplus investment in healthcare, a need for adequate healthcare facilities and the non-invasive aspects of the process are factors that have pushed for the market growth. The radiopharmaceuticals and nuclear medicine markets is further stimulated by innovations in radiotracers and radioisotopes. However, the lack of reimbursement policies, the short life span of radiopharmaceuticals and the stringent policies laid out by governing bodies could pose potential threats to the market on a global scale.  

Nuclear medicine processes provide help in diagnosing diseases with precise and detailed results at an early stage, long before the symptoms occur. Nuclear medicine tests entails less pain and offers information regarding specific organs with very little radiation. This aids the physicians to treat illnesses such as thyroid, cancer and bone metastasis. 

The diagnostics segment has sub-segments that are known as positron emission tomography (PET) and single-photon emission computed tomography (SPECT). The SPECT segment is likely to dominate the radiopharmaceutical/nuclear medicine diagnostics market in the future owing to the reduced costs and greater availability.

The therapeutics segment is further classified into alpha emitters, beta emitters, and brachytherapy isotopes. The beta emitters will be the foremost segment in the radiopharmaceutical therapeutics and nuclear medicine market.

Some of the players operating in the radiopharmaceuticals and nuclear medicine market includes Cardinal Health Inc. Lantheus Medical Imaging Inc., GE Healthcare,  Eczacibasi-Monrol Nuclear Products, IBA Molecular Imaging, Bayer Healthcare, Nordion Inc, Bracco Imaging S.p.A, Advanced Accelerator Applications S.A.


Nuclear Medicine or Radiopharmaceuticals Market Segmentation:

By Type

  • Diagnostic Nuclear Medicine
  •  Spect Radiopharmaceuticals
  •  Tc-99m
  •  Tl-201
  •  Ga-67
  •  I-123
  •  Other Spect Isotopes
  •  Pet Radiopharmaceuticals
  •  F-18
  •  Ru-82
  •  Other Pet Isotopes
  • Therapeutic Nuclear Medicine
  •  Alpha Emitters
  •  Ra-223
  •  Beta Emitters
  •  I-131
  •  Y-90
  •  Sm-153
  •  Re-186
  •  Lu-177
  •  Other Beta Emitters
  •  Brachytherapy Isotopes
  •  I-125
  •  Ir-192
  •  Pd-103
  •  Cs-131
  •  Other Brachytherapy Isotopes

By Application

  • Diagnostic Applications
  • Spect Applications
  •  Cardiology
  •  Lymphoma
  •  Neurology
  •  Thyroid
  •  Other Spect Applications
  • Pet Applications
  •  Oncology
  •  Cardiology
  •  Neurology
  •  Other Pet Applications
  • Therapeutic Applications
  •  Thyroid
  •  Bone Metastasis
  •  Lymphoma
  •  Endocrine Tumors
  •  Other Therapeutic Applications

By Procedural Volume

  • Diagnostic Procedures
  •  Spect Radiopharmaceuticals
  •  Pet Radiopharmaceuticals
  • Therapeutic Procedures
  •  Beta Emitters
  •  Alpha Emitters
  •  Brachytherapy Isotopes

By Region

FutureWise Key Takeaways:

  •    Growth prospects
  •    SWOT analysis
  •    Key trends
  •    Key data-points affecting market growth

Objectives of the Study:

  • To provide with an exhaustive analysis on the nuclear medicine/pharmaceuticals  market by type, by application, by procedural volume and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
  • To forecast and evaluate micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific and the rest of the world
  • To record , evaluate and analyze competitive landscape mapping- technological advancements, product launches, expansions and mergers

Flexible Delivery Model:

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com


Need Assistance


UK : +44 141 628 9353
US : +1 347 709 4931


Contact Sales

What you get

  • Excel Dataset

  • Infographics

  • PDF Report

  • Market Overview

  • PowerPoint Presentation

What's included

  • Consumer Perception and Procurement

  • Competitive Analysis

  • What’s Next

  • Market Data Forecast

  • Risks and Opportunity Assessment

  • Market Trends and Dynamics